Skip to main content
Clinical Trials/NCT07656324
NCT07656324RecruitingNot Applicable

Epidemiology and Prognostic Analysis of Chinese Cancer Patients With Cancer-related Fatigue

Fudan University1 site in 1 country1,000,000 target enrollmentStarted: January 17, 2025Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
1,000,000
Locations
1

Study Overview

Brief Summary

This investigator-initiated study aims to evaluate the incidence and severity of cancer-related fatigue (CRF) in patients with malignant tumors, to analyze the influencing factors of CRF, and to explore its impact on anti-tumor treatment and prognosis.

Detailed Description

This investigator-initiated study aims to evaluate the incidence and severity of cancer-related fatigue (CRF) in patients with malignant tumors, to analyze the influencing factors of CRF, and to explore its impact on anti-tumor treatment and prognosis. Using patient-completed questionnaires, combined with outpatient visit records and telephone follow-up, this study will explore the following aspects:

Assess the incidence and severity of cancer-related fatigue in patients with malignant tumors.

Analyze the influencing factors of cancer-related fatigue, including tumor type, treatment regimen, disease stage, efficacy of anti-tumor therapy, adverse events associated with anti-tumor therapy, and concomitant medications.

Evaluate the impact of cancer-related fatigue on anti-tumor treatment and prognosis.

Assess the multidimensional state and severity of cancer-related fatigue in patients with malignant tumors using the Brief Fatigue Inventory - Cancer (BFI-C) and the Multidimensional Fatigue Symptom Inventory - Short Form (MFSI-SF).

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Cross Sectional

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Male or female, aged 18 years or older.
  • Able to understand the purpose of this survey study, willing to participate, and able to sign an informed consent form.
  • Malignant tumor confirmed histologically or cytologically.

Exclusion Criteria

  • Pregnant or breastfeeding women.
  • Patients with acute or chronic infections, or those with other serious medical conditions that, in the investigator's judgment, make them unsuitable for this study.
  • Patients with two or more concurrent malignant tumors (excluding the following: cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and papillary thyroid carcinoma).
  • Patients with psychiatric illness or mental disorders, poor compliance, or who are unable to cooperate and report treatment responses.
  • Patients with severe organic disease or major organ failure, such as decompensated heart, lung, liver, or kidney failure.
  • Patients with other conditions that, in the investigator's opinion, make them unsuitable for participation in this study.

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Hongxia Wang

Pro

Fudan University

Study Sites (1)

Loading locations...

Similar Trials